Dabrafenib (GSK2118436)

目录号：S2807

Dabrafenib (GSK2118436) Chemical Structure

Molecular Weight(MW): 519.56

Dabrafenib (GSK2118436)是一种突变型BRAFV600特异性抑制剂，无细胞试验中IC50为0.7 nM，作用于B-Raf(wt)和c-Raf效果分别低7和9倍。

规格 价格 库存 购买数量  
RMB 1481.39 现货
RMB 733.64 现货
RMB 1056.75 现货
RMB 1394.46 现货
RMB 2235.84 现货
RMB 3261.37 现货
有超大折扣
大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834   |   Email：info@selleck.cn

客户使用Selleck该产品发表文献21篇：

客户使用该产品的9个实验数据：

  • BRAFi/MEKi-resistant A375DR and the parental A375 cells were treated with 2 μM vorinostat and/or the combination of 0.125 μM dabrafenib and 5 nM trametinib. Protein lysates were harvested after 72 hr. Western blot analysis was carried out for p-MEK and p-P90RSK as indicators of activation of MAPK pathway, ac-H3 as indicator for levels of acetylated histone H3 and a-tubulin as a loading control.

    Cell, 2018, 173(6):1413-1425. Dabrafenib (GSK2118436) purchased from Selleck.

    A375P cells were treated with vehicle, the BRAF inhibitor GSK2118436, the MEK inhibitor GSK1120212, 10 uM HCQ, or the indicated combinations. Shown are 48-hour immunoblots directed against the indicated proteins.

    J Clin Invest 2014 24(3), 1406-17. Dabrafenib (GSK2118436) purchased from Selleck.

  • Levels of pERK and tERK in the CLL cells derived from PBMC were measured by Western blot. We used vemurafenib, dabrafenib, and trametinib (0.07 uM) as indicated. One of 3 independent experiments with similar results is shown. CLL cells exposed to dabrafenib or vemurafenib had an elevated pERK/tERK ratio as compared with vehicle (P < 0.01).

    J Clin Invest 2014 124(11), 5074-84. Dabrafenib (GSK2118436) purchased from Selleck.

    Immunoblotting of whole-cell lysates of WM1366 exposed to the indicated drugs for 48 hours using specific antibodies for phospho-acetyl CoA carboxylase (p-ACC), total acetyl CoA carboxylase (t-ACC), phospho-ERK1/2 (p-ERK1/2), and total ERK1/2 (t-ERK1/2). Immunoblots were quantified using ImageJ. The ratio of phosphorylated to total protein normalized to control is shown above the respective blots.

    Clin Cancer Res, 2018, 24(5):1090-1102. Dabrafenib (GSK2118436) purchased from Selleck.

  • Braf−/− ER(TM)-HRAS(G12V) MEFs were transduced with retroviral constructs encoding the indicated BRAF proteins and treated with 4-HT to release oncogenic RAS, or ethanol as a control. Following incubation with 1 μM vemurafenib, 1 μM dabrafenib or DMSO as a control for 4 h, cells were subjected to western blot analysis with the indicated antibodies.

    Leukemia, 2016, 30(4):937-46. Dabrafenib (GSK2118436) purchased from Selleck.

    Western blots for untreated, early, and late tumors.

    Cancer research, 2018, 78(2):542-557. Dabrafenib (GSK2118436) purchased from Selleck.

  • Dabrafenib alleviates acetaminophen-induced hepatotoxicity in mice. Mice were treated with 300 mg/kg acetaminophen (i.p.), with or without pretreatment with 300 mg/kg or 100 mg/kg dabrafenib (p.o.).TUNEL staining for nuclear DNA fragmentation in mouse liver cells.

    Cell Death Dis 2014 5, e1278. Dabrafenib (GSK2118436) purchased from Selleck.

    The effects of inhibitors of mutant BRAFV600 inhibitor dabrafenib on cancer cell growth were evaluated by the MTT assay. Cell growth inhibition of FRO and SW1736 cell lines induced by dabrafenib.

    Transl Res 2014 10.1016/j.trsl.2014.06.005. Dabrafenib (GSK2118436) purchased from Selleck.

  • Western blot analysis of p-Erk and total ERK in A375 melanoma cell line after treatment with different doses of Dabrafenib for 48 hours (A). p-ERK signal was normalized with total ERK signal (B), SD and means of the normalized p-ERK values were reported.

    PLoS One, 2016, 11(3):e0152104. Dabrafenib (GSK2118436) purchased from Selleck.

产品安全说明书

Raf抑制剂选择性比较

生物活性

产品描述 Dabrafenib (GSK2118436)是一种突变型BRAFV600特异性抑制剂，无细胞试验中IC50为0.7 nM，作用于B-Raf(wt)和c-Raf效果分别低7和9倍。
靶点
B-Raf (V600E) [3]
(Cell-free assay)		 B-Raf [3]
(Cell-free assay)		 C-Raf [3]
(Cell-free assay)
0.7 nM 5.2 nM 6.3 nM
体外研究

Dabrafenib对Raf激酶具有选择性，对B-Raf的活性比其它测试过的91%的激酶高400倍。 Dabrafenib抑制B-RafV600E激酶，导致ERK磷酸化降低和抑制细胞的增值，在特异性编码突变的B-RafV600E的癌细胞中细胞停滞在G1期。
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NXz6c4Z3U2mwYYPlJGF{e2G7 NXSxR4xyUW6qaXLpeIlwdiCxZjDOMZRmem2rbnHsJGhqeyC2YXfn[YQhSi2UYX[gWlYxOEVibYX0ZY51KGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBqdnOnY4SgZ4VtdHNiY3:t[ZhxemW|c3nu[{BETEN|NzDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCkaX;0bY56dGG2ZXStUWVMKHC{b4TlbY4heGixc4Doc5J6dGG2aX;uJIJ6KEGucHjhV4Nz\WWwIHHzd4F6KHerdHigTWM2OCCxZjCwMlAxODdizszN NH7yRVAzPDlyME[3Ny=>
SK-MEL-28 NF\LWYVMcW6jc3WgRZN{[Xl? NWPhXXdKOSCq NHH0R3pKdmirYnn0bY9vKG:oIFKtVoFnKFZ4MEDFJI12fGGwdDDpckBpfW2jbjDTT{1OTUxvMkigZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4hTVKNIIDoc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gNE4xODRizszN MY[yOFkxODZ5Mx?=
HepG2 MlnVT4lv[XOnIFHzd4F6 MW\Jcohq[mm2aX;uJI9nKEJvUnHmJHY3ODCHIH31eIFvfCCrbjDoeY1idiCKZYDHNkBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCHUlugdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjByNDFOwG0> NVv1UWdiOjR7MEC2O|M>
COLO205 NHOwd|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFX6WG5KdmirYnn0bY9vKG:oIHj1cYFvKEORTF:yNFUh[2WubDDwdo9tcW[ncnH0bY9vKHerdHigTWM2OCCxZjCwMlAxPyEQvF2= MlTGNlQ6ODB4N{O=
HepG2 MlXTSpVv[3Srb36gRZN{[Xl? MoDpOFUhdWmw NHrFNolFVVOR NYfwO3B7UW6qaXLpeIlwdiCxZjDBcIs2KGmwIGTHSk1j\XSjLYP0bY12dGG2ZXSgbJVu[W5iSHXwS|Ih[2WubIOgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5iU33h[FIheGixc4Doc5J6dGG2aX;uJJRz\WG2ZXSg[o9zKDR3IH3pcpMheHKrb4KgeI8hXEeILXLleIEhe3SrbYXsZZRqd25ibXXhd5Vz\WRiYX\0[ZIhPjBibXnud{BjgSCxZInzd4V6KGKub4Sgd4Nidm6ncjDhcoFtgXOrczD3bZRpKEmFNUCgc4YhOy55IN88US=> NXnvR4ZmOjR7MEC2O|M>
HFF NEK0cZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGCzbG8yOCEQvF2= M4\keFczKGh? NXzOXJNGTE2VTx?= M2DGfWlvcGmkaYTpc44hd2ZicILvcIln\XKjdHnvckBw\iCqdX3hckBJTkZiY3XscJMhcGG{Yn;ybY5oKHerbHSgeJlx\SCELWLh[kB4cXSqIFnDOVAhd2ZiMzFOwG0> Mne1NlM5PDRyM{i=
SK-MEL-28 MmHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3PNVAh|ryP M{ezVVczKGh? NEC1RVRFVVOR MU\Jcohq[mm2aX;uJI9nKEJvUnHmJHY3ODCHIH31eIFvfC2mcnn2[Y4hW0tvTVXMMVI5KGOnbHygdJJwdGmoZYLheIlwdiC5aYToJGlEPTBib3[gNE4xPDNizszN MYiyN|g1PDB|OB?=
A375P-F11 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\HNVAh|ryP MkTUO|IhcA>? M3HqcGROW09? NELwSWVKdmirYnn0bY9vKG:oIFKtVoFnKFZ4MEDFJI12fGGwdD3kdol3\W5iQUO3OXAuTjFzIHPlcIwheHKxbHnm[ZJifGmxbjD3bZRpKEmFNUCgc4YhOC5yN{Gg{txO M2XtVVI{QDR2MEO4
MALME-3M MoXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TIUFExKM7:TR?= M3;RbVczKGh? NXjuT3NOTE2VTx?= MVzJR|UxRTFibl2= NXTrSpk3OjN6NESwN|g>
UACC-62 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPUNVAh|ryP M37QcVczKGh? NF2wfJlFVVOR MUDJR|UxRTFibl2= NIGyRpQzOzh2NECzPC=>
C32TG NWLYNZpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX6xNEDPxE1? M2KwUlczKGh? MmTmSG1UVw>? NUjoTlhLUUN3ME2xJI5O NVTvUXFmOjN6NESwN|g>
SK-MEL-1 Mn;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULhUHQ5OTBizszN M4HGO|czKGh? MlPGSG1UVw>? MWLJR|UxRTJibl2= M2LvWVI{QDR2MEO4
M14 NH;ucGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;EdGcyOCEQvF2= MmX2O|IhcA>? MWPEUXNQ MXnJR|UxRTJibl2= Mk[0NlM5PDRyM{i=
SK-MEL-28 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXQNVAh|ryP M1jlZlczKGh? M{HxU2ROW09? NV\UfZFqUUN3ME2zJI5O MnfSNlM5PDRyM{i=
A375 NVn4NYlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7tc4YyOCEQvF2= MXG3NkBp Mk\1SG1UVw>? M4PlXmlEPTB;NDDuUS=> MlvxNlM5PDRyM{i=
DU-4475 MkLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfnbmZHOTBizszN MWG3NkBp M4j2UGROW09? NV;KPVl2UUN3ME21JI5O MYGyN|g1PDB|OB?=
UACC-257 M2TaWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rUdVExKM7:TR?= NEP6Zm04OiCq NV3TemRZTE2VTx?= MkHWTWM2OD14IH7N M1HhO|I{QDR2MEO4
Colo 205 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fjV|ExKM7:TR?= NG\yOI04OiCq MlLkSG1UVw>? MXHJR|UxRTdibl2= MX:yN|g1PDB|OB?=
SK-MEL-3 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWWxNEDPxE1? NWHQdG5{PzJiaB?= NIfSVYJFVVOR M1v0XmlEPTB;NzDuUS=> MXWyN|g1PDB|OB?=
SH-4 MmPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDHNVAh|ryP Mk\EO|IhcA>? MmPCSG1UVw>? Ml21TWM2OD16IH7N NWW1SYtlOjN6NESwN|g>
A101D M4rNSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVWxNEDPxE1? MlLJO|IhcA>? NGfyVnRFVVOR M1HY[mlEPTB;OTDuUS=> MmrjNlM5PDRyM{i=
ES-2 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUKxNEDPxE1? MUS3NkBp NV3MXmZzTE2VTx?= NF3ZeYpKSzVyPUWzJI5O Mn;pNlM5PDRyM{i=
HT-29 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTSNVAh|ryP MlPSO|IhcA>? MX3EUXNQ MUXJR|UxRTZ4IH7N NFzxUoUzOzh2NECzPC=>
SW1417 NUS2WHlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzHdppnOTBizszN NHT0WI84OiCq M2LkdWROW09? MVnJR|UxRTF3ODDuUS=> NHrkW3EzOzh2NECzPC=>
SW872 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIK2NYEyOCEQvF2= MoHHO|IhcA>? M{GwT2ROW09? MVnJR|UxRTN5NzDuUS=> M4T0N|I{QDR2MEO4
RKO NYf5OnI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzYU3drOTBizszN MYC3NkBp M3LD[2ROW09? NHrmZZRKSzVyPUKuOVIzKM7:TR?= MmPzNlM5PDRyM{i=
A673 M3fFWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Pl[VExKM7:TR?= NGTyXng4OiCq MkT0SG1UVw>? MmP0TWM2OD1zMDFOwG0> MofZNlM5PDRyM{i=
GCT NYP5b25bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXH6Vm0{OTBizszN MVG3NkBp M3nHWmROW09? NGjjSGZKSzVyPUGwJO69VQ>? MXiyN|g1PDB|OB?=
WM-115 NHT1TpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYf6cmc5OTBizszN M4HOXVczKGh? NWHLZ45CTE2VTx?= NGXVXodKSzVyPUWgcm0> NFG1[XUzOzh2NECzPC=>
YUMAC MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYexNEDPxE1? NGO0ZXc4OiCq M2nTcmROW09? NVjYXGhtUUN3ME21JI5O M37PUFI{QDR2MEO4
OV-90 NUTZbXl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXnU|RXOTBizszN M3vGOlczKGh? NETwZ49FVVOR M3fWZmlEPTB;Mkmgcm0> MYqyN|g1PDB|OB?=
NCI-H508 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlixNVAh|ryP NGjMOVQ4OiCq MnPXSG1UVw>? Mk\KTWM2OD1zMDFOwG0> M{XBNlI{QDR2MEO4
MDA-MB-231 Mn7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnqeXdROTBizszN NXrJWphKPzJiaB?= M2Xsb2ROW09? MnnQTWM2OD1zMDFOwG0> MUiyN|g1PDB|OB?=
SW756 Ml[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mln2NVAh|ryP NFf3OlU4OiCq M{i2O2ROW09? NIeyfFJKSzVyPUGwJO69VQ>? NWjMWG1tOjN6NESwN|g>
SW-837 NYHvPYZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\zR2dvOTBizszN MV23NkBp MmT6SG1UVw>? NYXkVGJPUUN3ME2xNEDPxE1? M4rWUVI{QDR2MEO4
UMUC-3 M2PlZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVixNEDPxE1? NYTudFdrPzJiaB?= NYnDVXU4TE2VTx?= NYfQcZF3UUN3ME2xNEDPxE1? NFH5WGUzOzh2NECzPC=>
LS-174T Mmr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjidGF7OTBizszN M3;OOlczKGh? NHLwW3pFVVOR Mm\QTWM2OD1zMDFOwG0> NVPncotjOjN6NESwN|g>
A549 NHLVeItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWmxNEDPxE1? M2mzeFczKGh? M3TvXWROW09? NVLKeY1JUUN3ME2xNEDPxE1? MVKyN|g1PDB|OB?=
SHP-77 MnG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmm2NVAh|ryP M2H4UlczKGh? NXXHeVRoTE2VTx?= Ml:yTWM2OD1zMDFOwG0> MmL2NlM5PDRyM{i=
SW480 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37telExKM7:TR?= MkLTO|IhcA>? MoD1SG1UVw>? Mn3pTWM2OD1zMDFOwG0> NHKyTmczOzh2NECzPC=>
DLD-1 NI\aXldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDyNVAh|ryP Mln0O|IhcA>? MU\EUXNQ MnW4TWM2OD1zMDFOwG0> NELzbIUzOzh2NECzPC=>
HCT-116 NELBWlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPuelMyOCEQvF2= MVq3NkBp NVXvXmFMTE2VTx?= NV\aSGQ2UUN3ME2xNEDPxE1? Mk\5NlM5PDRyM{i=
NCI-H747 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LXblExKM7:TR?= NX;me4puPzJiaB?= NF7FTXlFVVOR MYfJR|UxRTFyIN88US=> NYrQZpZSOjN6NESwN|g>
T-84 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnMNVAh|ryP MV[3NkBp M37XN2ROW09? NUC0eFhYUUN3ME2xNEDPxE1? NEjYW|UzOzh2NECzPC=>
NCI-H460 M2DxR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDjfXpbOTBizszN NFvYfJQ4OiCq NVLCb2psTE2VTx?= NIewOIJKSzVyPUGwJO69VQ>? Mly2NlM5PDRyM{i=
Calu-6 MkXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXST|gyOCEQvF2= MVu3NkBp NIXtbmxFVVOR MmT5TWM2OD1zMDFOwG0> M2C5T|I{QDR2MEO4
HCC-2998 MknZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmT1NVAh|ryP MUK3NkBp MXvEUXNQ MWLJR|UxRTFyIN88US=> NXfMbnhYOjN6NESwN|g>
LS1034 M4e4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFX4cnYyOCEQvF2= NGfndJM4OiCq NFOyPYFFVVOR M1zCO2lEPTB;MUCg{txO M4nmclI{QDR2MEO4
CHP-212 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLmNVAh|ryP NEGyVnQ4OiCq NVu5OJZkTE2VTx?= Mm\0TWM2OD1zMDFOwG0> NFHr[3QzOzh2NECzPC=>
SK-N-AS NYnUc49ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17HcVExKM7:TR?= Mn3qO|IhcA>? M{\obGROW09? NVuwXJZkUUN3ME2xNEDPxE1? M3PhfVI{QDR2MEO4
BFTC-905 MoXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvoNVAh|ryP MYm3NkBp M17HOWROW09? NX;WVnA1UUN3ME2xNEDPxE1? NWfKPXhROjN6NESwN|g>
HuT78 M1HDZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrUdGFKOTBizszN MWq3NkBp NGXGUGVFVVOR M2X4RWlEPTB;NUKgcm0> NVHiRlBmOjN6NESwN|g>
RPMI-8226 NXP6fmpyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWGxNEDPxE1? MknjO|IhcA>? M4LMeWROW09? MV7JR|UxRTJ4MzDuUS=> NInFNm4zOzh2NECzPC=>
BC-3 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXyxNEDPxE1? M4izUlczKGh? Mny0SG1UVw>? Ml7uTWM2OD1{N{egcm0> NVnKSXZ7OjN6NESwN|g>
ACHN NXLOVnN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHzVoVxOTBizszN M{OwT|czKGh? NFjjXpFFVVOR NFyxbZdKSzVyPUK5OEBvVQ>? M3LuXFI{QDR2MEO4
JRT3-T35 MlLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVSxNEDPxE1? NX:5OllvPzJiaB?= NIOyPG1FVVOR MnXjTWM2OD1{OUWgcm0> NWPkbFhsOjN6NESwN|g>
SK-MES-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoGyNVAh|ryP NELmfmE4OiCq MWPEUXNQ M135emlEPTB;M{K5JI5O MnfqNlM5PDRyM{i=
CESS MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrnNVAh|ryP MoPaO|IhcA>? NVjvblZTTE2VTx?= MYjJR|UxRTR7NzDuUS=> NV\0b5RmOjN6NESwN|g>
H4 NUXQPXpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\WNVAh|ryP NYXZVJhEPzJiaB?= NF7XdXlFVVOR NXjxS3FxUUN3ME22NVkhdk1? NVjxdIVqOjN6NESwN|g>
BC-1 NXzQ[5lyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGP1dIsyOCEQvF2= NVvXUFdFPzJiaB?= NX22VnhyTE2VTx?= MWfJR|UxRTdyNDDuUS=> MnzkNlM5PDRyM{i=
DB M3XTdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVWxR21UOTBizszN MUO3NkBp M2XzRmROW09? MnrzTWM2OD16N{Ogcm0> NHPNdVEzOzh2NECzPC=>
RPMI-6666 NUHzTFF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGX6UFIyOCEQvF2= NEDBZ|I4OiCq M4LCXWROW09? NHHoSXZKSzVyPUmyPEBvVQ>? M{DU[lI{QDR2MEO4
MC/CAR NXnVSI1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGn1V2cyOCEQvF2= M1T5V|czKGh? NWH4fm8xTE2VTx?= NHTUN49KSzVyPUGuNFAzKM7:TR?= MYqyN|g1PDB|OB?=
SNU-1 M3yxXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjicJhoOTBizszN Mn7YO|IhcA>? M3;vfmROW09? MoqwTWM2OD1zLkWwNUDPxE1? MV6yN|g1PDB|OB?=
CEM/C1 NHjWN49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIe4bJEyOCEQvF2= NHfhb5U4OiCq NXHoT2c4TE2VTx?= MVLJR|UxRTFwN{ezJO69VQ>? M2jUN|I{QDR2MEO4
GDM-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYixNEDPxE1? M3fBVFczKGh? NWe0WJhITE2VTx?= M3TtZ2lEPTB;MT65PVch|ryP MnfiNlM5PDRyM{i=
HT-1080 M2jkN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PUXlExKM7:TR?= MYS3NkBp M2njU2ROW09? NIeweJFKSzVyPUKuNFA1KM7:TR?= MoKyNlM5PDRyM{i=
HL-60 MmT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYSxNEDPxE1? NVXsO4xuPzJiaB?= NXnv[JZxTE2VTx?= NHvYeVNKSzVyPUKuNVc5KM7:TR?= NIrucGUzOzh2NECzPC=>
C3A NVvFUpFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XhVlExKM7:TR?= M4PQSlczKGh? MlHQSG1UVw>? NGHLdpVKSzVyPUWuOFE1KM7:TR?= MWqyN|g1PDB|OB?=
MES-SA NWn5fZk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUmxNEDPxE1? NI\iWXY4OiCq NF:1Vo5FVVOR MYLJR|UxRTZwOUi5JO69VQ>? MlrGNlM5PDRyM{i=
22Rv1 MkXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVWxNEDPxE1? MXi3NkBp MlntSG1UVw>? Mkj2TWM2OD1zMDFOwG0> NEjMSYczOzh2NECzPC=>
647-V M1vRRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYexNEDPxE1? M3K5SVczKGh? M3TxSGROW09? MmjZTWM2OD1zMDFOwG0> M4LmflI{QDR2MEO4
786-O M1\hT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\qNVAh|ryP MorGO|IhcA>? MV3EUXNQ NWLYWotpUUN3ME2xNEDPxE1? NUjIfXFyOjN6NESwN|g>
A172 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfyN|EyOCEQvF2= MWO3NkBp M4fDZWROW09? MX3JR|UxRTFyIN88US=> MWeyN|g1PDB|OB?=
A204 Mk\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrtNVAh|ryP NXTRTmM2PzJiaB?= MmO4SG1UVw>? NHrwVGNKSzVyPUGwJO69VQ>? M1jvbFI{QDR2MEO4
A427 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nwblExKM7:TR?= M1XZ[FczKGh? NVL6TFVjTE2VTx?= MWHJR|UxRTFyIN88US=> MYOyN|g1PDB|OB?=
A431 NXSzcmQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLONVAh|ryP MWm3NkBp NGrsfJlFVVOR NHLGUplKSzVyPUGwJO69VQ>? M1jFelI{QDR2MEO4
A2780 Mm\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XPVFExKM7:TR?= NIjuZ4Q4OiCq MUXEUXNQ M4DS[WlEPTB;MUCg{txO M2nHOVI{QDR2MEO4
ARH-77 NXKyZ4RiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jQWFExKM7:TR?= NETuNoM4OiCq Mm\hSG1UVw>? NF3iUXFKSzVyPUGwJO69VQ>? NYPBcoJuOjN6NESwN|g>
Be(2)C MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHzdpZ1OTBizszN MWO3NkBp NU\zN3I1TE2VTx?= MXHJR|UxRTFyIN88US=> NH3DTY4zOzh2NECzPC=>
BT-20 M2jkWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULvUWZDOTBizszN MXK3NkBp NEfEcFdFVVOR MkXITWM2OD1zMDFOwG0> NWHobpozOjN6NESwN|g>
BxPc3 M2O2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\sdlFkOTBizszN MlnMO|IhcA>? Mki2SG1UVw>? Mn[3TWM2OD1zMDFOwG0> NEPIO2IzOzh2NECzPC=>
C-4 I MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHENVAh|ryP MV:3NkBp M1fid2ROW09? NXzsfHhtUUN3ME2xNEDPxE1? NWfJdGNUOjN6NESwN|g>
C33A M1PEeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYSxNEDPxE1? MXm3NkBp M{XYOWROW09? NEnPXZZKSzVyPUGwJO69VQ>? MkC1NlM5PDRyM{i=
CAL-27 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX2xNEDPxE1? M3v4VVczKGh? NFHSdlVFVVOR M3rNTWlEPTB;MUCg{txO M2PhXlI{QDR2MEO4
CAL-62 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fROFExKM7:TR?= M1XMbVczKGh? M{GxVGROW09? MXPJR|UxRTFyIN88US=> M37ZTlI{QDR2MEO4
Calu-3 NXi1PFl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\pb4xTOTBizszN Mn6yO|IhcA>? M4fsTmROW09? NE\wXlZKSzVyPUGwJO69VQ>? MYGyN|g1PDB|OB?=
CaOV3 M3fKdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PsOFExKM7:TR?= NFSySIk4OiCq NGnnUZZFVVOR MVTJR|UxRTFyIN88US=> M{[xZlI{QDR2MEO4
CGTHW1 M3\xRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWexNEDPxE1? MUC3NkBp MWrEUXNQ M{fRb2lEPTB;MUCg{txO M130b|I{QDR2MEO4
CHL-1 Mn62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFq4OVEyOCEQvF2= NFrqN4w4OiCq NITwbmJFVVOR NIL4RmJKSzVyPUGwJO69VQ>? NWW2d2ZrOjN6NESwN|g>
Colo320DM Mle5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjsd28yOCEQvF2= NXHtXop7PzJiaB?= NYq3NVBKTE2VTx?= MlLETWM2OD1zMDFOwG0> MX[yN|g1PDB|OB?=
Colo704 MnzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3yNVAh|ryP MnnNO|IhcA>? NGLPS2hFVVOR M2O2T2lEPTB;MUCg{txO MViyN|g1PDB|OB?=
COR-L23 NXOwS4ZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHr3doMyOCEQvF2= Mn62O|IhcA>? NHTWSmtFVVOR MnHWTWM2OD1zMDFOwG0> MX:yN|g1PDB|OB?=
CRO-AP2 NHjNdlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PJWVExKM7:TR?= NULHbIc{PzJiaB?= NHSwNotFVVOR MVzJR|UxRTFyIN88US=> M{\yNlI{QDR2MEO4
Daudi M2PPSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jkS|ExKM7:TR?= NULvXZNMPzJiaB?= MnLySG1UVw>? MVzJR|UxRTFyIN88US=> MYKyN|g1PDB|OB?=
DOTC 24510 NYP6XG57T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLsWFB1OTBizszN NVO1eZBkPzJiaB?= MoXOSG1UVw>? M{S0VGlEPTB;MUCg{txO NIDBcWIzOzh2NECzPC=>
DU-145 MmrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPoNVAh|ryP NXTmelJPPzJiaB?= NGXGSohFVVOR MWrJR|UxRTFyIN88US=> MXGyN|g1PDB|OB?=
EB-3 NXPaS5lTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[3SI4yOCEQvF2= NYPOeXdzPzJiaB?= NVrMeWs{TE2VTx?= MmjZTWM2OD1zMDFOwG0> M4f5c|I{QDR2MEO4
EFM-19 NEnHclRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2T6NFExKM7:TR?= MWS3NkBp NWT5VJBQTE2VTx?= NHXxfm1KSzVyPUGwJO69VQ>? NUK3WnljOjN6NESwN|g>
EKVX NYnKSVRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkH5NVAh|ryP NV:2TJBpPzJiaB?= MkP4SG1UVw>? NWTlT25mUUN3ME2xNEDPxE1? M2PwZ|I{QDR2MEO4
FaDu M3T2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnyNVAh|ryP MYC3NkBp M1LremROW09? MYXJR|UxRTFyIN88US=> MkHENlM5PDRyM{i=
G401 MmD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXqNVAh|ryP M2W3OFczKGh? NIOzN|hFVVOR NV;jZ|drUUN3ME2xNEDPxE1? Mn:zNlM5PDRyM{i=
HCC-70 M4TPZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX6xNEDPxE1? MWW3NkBp NHLM[JNFVVOR M4rGc2lEPTB;MUCg{txO NXLsUYhJOjN6NESwN|g>
HCC-1954 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\MNVAh|ryP NV;FSVFFPzJiaB?= NI\5PVBFVVOR M3PPNGlEPTB;MUCg{txO M4nBW|I{QDR2MEO4
Hela NXPmRVVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nvelExKM7:TR?= NHvEWFU4OiCq NYnZb|dYTE2VTx?= NX3rZ2NFUUN3ME2xNEDPxE1? NEXVWlAzOzh2NECzPC=>
Hep3B NEXGXldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWftWWcyOTBizszN MmXoO|IhcA>? MnjzSG1UVw>? NGP2bVdKSzVyPUGwJO69VQ>? MkXrNlM5PDRyM{i=
HMCB NHTpbINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzvc|EyOCEQvF2= NXOyfpVQPzJiaB?= NY\1dGNITE2VTx?= MWnJR|UxRTFyIN88US=> M1TodFI{QDR2MEO4
HN5 Mk\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1q2T|ExKM7:TR?= NYXXZ4E1PzJiaB?= NULndpppTE2VTx?= NH7YZ4NKSzVyPUGwJO69VQ>? MknLNlM5PDRyM{i=
HOS NYHUbHdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUWxNEDPxE1? M3y4UFczKGh? NX\FeY03TE2VTx?= MoDBTWM2OD1zMDFOwG0> NIjCenAzOzh2NECzPC=>
HPAF-II MnfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXztXYs1OTBizszN MUm3NkBp MUjEUXNQ NUXxc3lSUUN3ME2xNEDPxE1? M33se|I{QDR2MEO4
Hs746.T MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;vNVAh|ryP NXrRR3BUPzJiaB?= M2G1dWROW09? MUPJR|UxRTFyIN88US=> MXeyN|g1PDB|OB?=
HT MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkL2NVAh|ryP NHnCenM4OiCq NYrUemVlTE2VTx?= NU\XeldtUUN3ME2xNEDPxE1? M3XOOVI{QDR2MEO4
HT-3 NUnpPXBDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDZeXF1OTBizszN MYe3NkBp MlHuSG1UVw>? NI[1TI9KSzVyPUGwJO69VQ>? NVjlVZlXOjN6NESwN|g>
HuNS-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7qNVAh|ryP M1O0Z|czKGh? NUT6epZmTE2VTx?= MX7JR|UxRTFyIN88US=> MXqyN|g1PDB|OB?=
IGROV1 NYDWPYU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVOxNEDPxE1? M1G4PVczKGh? MWrEUXNQ MnfBTWM2OD1zMDFOwG0> M3LCSlI{QDR2MEO4
J82 NVLrZVM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPSNVAh|ryP M{K0dlczKGh? NXnxd4F[TE2VTx?= M3PBRmlEPTB;MUCg{txO M2TB[|I{QDR2MEO4
JM1 NELLdXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYOxNEDPxE1? MkDZO|IhcA>? MYXEUXNQ M1KzcmlEPTB;MUCg{txO NVLrWnV5OjN6NESwN|g>
Kato III M3nTcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3faXVExKM7:TR?= NVezbIg4PzJiaB?= MlS2SG1UVw>? MmPqTWM2OD1zMDFOwG0> NGG1dmUzOzh2NECzPC=>
KHOS-240S MoC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3[4e|ExKM7:TR?= NFzCe4s4OiCq NXX3TlN[TE2VTx?= NEnjXYtKSzVyPUGwJO69VQ>? NWTMXZVzOjN6NESwN|g>
KM-12 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;sb5gyOCEQvF2= M{e5VlczKGh? MXPEUXNQ NUHsfol4UUN3ME2xNEDPxE1? M1zWdFI{QDR2MEO4
KPL-1 NHPsUWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LURVExKM7:TR?= NUDDWpdFPzJiaB?= NGnxWnFFVVOR NIjPdXBKSzVyPUGwJO69VQ>? MYGyN|g1PDB|OB?=
KYSE-30 MoPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;K[lgyOCEQvF2= NELqdYg4OiCq NYPjZ5NKTE2VTx?= NVfne5V5UUN3ME2xNEDPxE1? MYqyN|g1PDB|OB?=
LNCaP MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHvNVAh|ryP NHHnTVg4OiCq MkfQSG1UVw>? M{XibmlEPTB;MUCg{txO NEjsfm4zOzh2NECzPC=>
MCF-7 M1;yPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2D6bFExKM7:TR?= NVrYXnNkPzJiaB?= NEHjNGZFVVOR MnLKTWM2OD1zMDFOwG0> MnLONlM5PDRyM{i=
MC-IXC M{O3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\2XlMyOCEQvF2= NVy3T4JnPzJiaB?= NUfBNnpXTE2VTx?= NIH0O29KSzVyPUGwJO69VQ>? MW[yN|g1PDB|OB?=
MDA-MB-175 VII NFj1OoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPUcJAyOCEQvF2= MYq3NkBp MUXEUXNQ MUjJR|UxRTFyIN88US=> MXWyN|g1PDB|OB?=
MDA-MB-468 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\jNVAh|ryP MkHXO|IhcA>? NEDRWWRFVVOR MUTJR|UxRTFyIN88US=> M3vKflI{QDR2MEO4
MiaPaCa NF7UbXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;jNVAh|ryP NYH1R5loPzJiaB?= NWTlPXJSTE2VTx?= M3m5dGlEPTB;MUCg{txO NEKzb5IzOzh2NECzPC=>
Molt-4 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zSc|ExKM7:TR?= MojHO|IhcA>? NY\lUYh{TE2VTx?= NVzhR5RUUUN3ME2xNEDPxE1? M{LNW|I{QDR2MEO4
NCI-ADR/RES NYXHNWhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHiwVHAyOCEQvF2= M2Tid|czKGh? NIjpO2RFVVOR NHrqRlNKSzVyPUGwJO69VQ>? Ml\rNlM5PDRyM{i=
NCI-H69 NIrQZY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWqxNEDPxE1? NW\lRpBJPzJiaB?= M{Htc2ROW09? M{S0fGlEPTB;MUCg{txO Mmq0NlM5PDRyM{i=
NCI-H82 NILsOGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjadZQyOCEQvF2= M4H0XFczKGh? MXPEUXNQ MoPiTWM2OD1zMDFOwG0> MXmyN|g1PDB|OB?=
NCI-N87 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYGxNEDPxE1? NIDVO5M4OiCq MWfEUXNQ NULhe3o{UUN3ME2xNEDPxE1? NYX2VFdDOjN6NESwN|g>
NCI-H146 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;GTY5LOTBizszN MU[3NkBp NH\qfWJFVVOR M1;qSGlEPTB;MUCg{txO M2HZS|I{QDR2MEO4
NCI-H157 M3vjPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnndG42OTBizszN NETNZpI4OiCq MX\EUXNQ MYfJR|UxRTFyIN88US=> NWe2RYpuOjN6NESwN|g>
NCI-H187 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPGNVAh|ryP NIfFOFE4OiCq MXrEUXNQ NIHKNG1KSzVyPUGwJO69VQ>? NUHPXY9JOjN6NESwN|g>
NCI-H209 NV\rd3VbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV:xNEDPxE1? M4nYclczKGh? M3jlNGROW09? NEnDbWZKSzVyPUGwJO69VQ>? NYHSfGFjOjN6NESwN|g>
NCI-H226 M4XrVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1raTlExKM7:TR?= NX;oPFNoPzJiaB?= NFq1WpdFVVOR MljjTWM2OD1zMDFOwG0> MVKyN|g1PDB|OB?=
NCI-H292 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\nVIgzOTBizszN MoXHO|IhcA>? NF\qTmNFVVOR M1XKOGlEPTB;MUCg{txO NEH6XYkzOzh2NECzPC=>
NCI-H322 NEjBT2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;rXVMzOTBizszN MV23NkBp NX;F[odHTE2VTx?= NUHWSW1PUUN3ME2xNEDPxE1? M1HCV|I{QDR2MEO4
NCI-H358 NG\mRoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLXNVAh|ryP NUTKcmVDPzJiaB?= MYTEUXNQ MmrOTWM2OD1zMDFOwG0> M3HvdFI{QDR2MEO4
NCI-H520 NVzy[JZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jYeVExKM7:TR?= NIXRR3E4OiCq MlrrSG1UVw>? MVjJR|UxRTFyIN88US=> MkXmNlM5PDRyM{i=
NCI-H526 NIPOcVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPiNVAh|ryP M3f4OFczKGh? NVH1Uph5TE2VTx?= MnLTTWM2OD1zMDFOwG0> MnTZNlM5PDRyM{i=
NCI-H630 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPMNVAh|ryP M3TFVVczKGh? MXHEUXNQ M333RWlEPTB;MUCg{txO NYjObWVvOjN6NESwN|g>
NCI-H661 MmLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\nXJMyOCEQvF2= MlTqO|IhcA>? MUfEUXNQ M2K1WmlEPTB;MUCg{txO Moq3NlM5PDRyM{i=
NCI-H716 M{jmXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHSPYwyOCEQvF2= MXS3NkBp MXrEUXNQ MX\JR|UxRTFyIN88US=> NWjqTYo6OjN6NESwN|g>
NCI-H1563 NV[5[I5XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnRdmUyOCEQvF2= NILVT484OiCq MkHsSG1UVw>? MW\JR|UxRTFyIN88US=> MX[yN|g1PDB|OB?=
NCI-H1792 M2nwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHrUFMyOCEQvF2= MWi3NkBp MofwSG1UVw>? NIDyRWJKSzVyPUGwJO69VQ>? MVuyN|g1PDB|OB?=
NCI-H2030 NUHrW2ZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17FbFExKM7:TR?= NHj6WIw4OiCq M{LZ[GROW09? NFnHdotKSzVyPUGwJO69VQ>? Moj3NlM5PDRyM{i=
NCI-H2052 M3;NfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLyNVAh|ryP NEPZWFY4OiCq MYXEUXNQ M2LXVmlEPTB;MUCg{txO NI\5c4ozOzh2NECzPC=>
NCI-H2122 M2HtTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUKxNEDPxE1? MlTFO|IhcA>? M3K3N2ROW09? M2XhdWlEPTB;MUCg{txO NFjBbGkzOzh2NECzPC=>
NCI-H2228 M2HkV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlGxNVAh|ryP NXzGWFZDPzJiaB?= MojMSG1UVw>? Mnf1TWM2OD1zMDFOwG0> NXi2ZZdHOjN6NESwN|g>
OE-19 MmfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUKxNEDPxE1? NWqzdlVHPzJiaB?= M4HlTGROW09? MmSyTWM2OD1zMDFOwG0> MV:yN|g1PDB|OB?=
OE-21 NFrCNnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XiO|ExKM7:TR?= NVPzdXBXPzJiaB?= NED2bXJFVVOR MVzJR|UxRTFyIN88US=> MUGyN|g1PDB|OB?=
OE-33 NGnJOVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULRfZhsOTBizszN Mne2O|IhcA>? MYrEUXNQ NEXoTWxKSzVyPUGwJO69VQ>? MXWyN|g1PDB|OB?=
OVCAR-3 MnPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUmxNEDPxE1? MnvUO|IhcA>? NHnQdmFFVVOR NFPodYFKSzVyPUGwJO69VQ>? NFXXPWUzOzh2NECzPC=>
OVCAR-4 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWixNEDPxE1? M3[1VFczKGh? NILWc5lFVVOR MVTJR|UxRTFyIN88US=> MWWyN|g1PDB|OB?=
OVCAR-5 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn[3NVAh|ryP MnzqO|IhcA>? MULEUXNQ NGjOTY1KSzVyPUGwJO69VQ>? Mn3GNlM5PDRyM{i=
P3HR-1 NF7iU2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIKxXokyOCEQvF2= MVK3NkBp NH7tVGlFVVOR NWH6dJVJUUN3ME2xNEDPxE1? NHywdnkzOzh2NECzPC=>
PC-3 MnjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33HRlExKM7:TR?= M2K4NlczKGh? NILHXVJFVVOR MWLJR|UxRTFyIN88US=> MX6yN|g1PDB|OB?=
Raji MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M124WVExKM7:TR?= NHfZUoI4OiCq MoDxSG1UVw>? NWrzbm5xUUN3ME2xNEDPxE1? MljWNlM5PDRyM{i=
RD M4WwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWKxNEDPxE1? M2WyT|czKGh? NV\lPZJpTE2VTx?= NWXYPIhsUUN3ME2xNEDPxE1? Mn[1NlM5PDRyM{i=
RD-ES MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\tc|ExKM7:TR?= NXXiOlFGPzJiaB?= NH\lcFBFVVOR NWrzPGQ3UUN3ME2xNEDPxE1? MX:yN|g1PDB|OB?=
RL NH3ZSJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLr[|dmOTBizszN MXq3NkBp M{P0SGROW09? NFG1TJpKSzVyPUGwJO69VQ>? M2PxcVI{QDR2MEO4
SaOS2 NE\yTIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvxR5NCOTBizszN MYK3NkBp MmHaSG1UVw>? M4TTXWlEPTB;MUCg{txO MnP3NlM5PDRyM{i=
SCC-9 Mne5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXuxNEDPxE1? Mn[3O|IhcA>? NF74S4RFVVOR NHTDN|BKSzVyPUGwJO69VQ>? NIfuS4czOzh2NECzPC=>
SCC-12 MkK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPCN3VvOTBizszN MVm3NkBp MoHpSG1UVw>? MnHRTWM2OD1zMDFOwG0> MlXuNlM5PDRyM{i=
SCC-13 NWPVdVhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3NSJEyOCEQvF2= MVe3NkBp NH;JR5NFVVOR M2PvSmlEPTB;MUCg{txO NYTCNHB2OjN6NESwN|g>
SCC-15 NVTuVFg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXKfZQyOCEQvF2= NEOwS2M4OiCq NHLkU2xFVVOR Mnr4TWM2OD1zMDFOwG0> NXTESIRQOjN6NESwN|g>
SCC-25 NULLbYJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYqxNEDPxE1? MkLYO|IhcA>? MlPZSG1UVw>? NFP6VWdKSzVyPUGwJO69VQ>? NXnZOpduOjN6NESwN|g>
SCLC-3 Mn\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDtNnIzOTBizszN NEjiZ2U4OiCq MnznSG1UVw>? MXzJR|UxRTFyIN88US=> M3f5bVI{QDR2MEO4
SF-268 MoTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUKxNEDPxE1? NGe4WXc4OiCq NWOye5VVTE2VTx?= MXrJR|UxRTFyIN88US=> NX6wVWNPOjN6NESwN|g>
SF-295 MlXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVyxNEDPxE1? NG\weo84OiCq NETZTo1FVVOR NV;qXI1PUUN3ME2xNEDPxE1? NVzTSZdxOjN6NESwN|g>
SJRH30 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfqPWUyOCEQvF2= NGrNXI84OiCq NYjxeYh2TE2VTx?= NEm4Vm1KSzVyPUGwJO69VQ>? M2L3NlI{QDR2MEO4
SK-BR-3 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\ZZYYyOCEQvF2= MWq3NkBp NUe1WWF5TE2VTx?= NV7YboJCUUN3ME2xNEDPxE1? NHrucFczOzh2NECzPC=>
SK-LMS-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVGxNEDPxE1? M3K5O|czKGh? MY\EUXNQ MWnJR|UxRTFyIN88US=> NHfzVGozOzh2NECzPC=>
SK-N-DZ NU\keY9XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7sNVAh|ryP MVq3NkBp M1jJU2ROW09? MmqzTWM2OD1zMDFOwG0> NInYN4czOzh2NECzPC=>
SK-N-F1 NHmyPGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHZdVVNOTBizszN NXv3NJhlPzJiaB?= NFLGZm5FVVOR NHThNHZKSzVyPUGwJO69VQ>? M{\wOlI{QDR2MEO4
SKOV-3 MkjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1u2blExKM7:TR?= NXjkfFRRPzJiaB?= MUTEUXNQ MUfJR|UxRTFyIN88US=> NV65cmg3OjN6NESwN|g>
SK-UT-1 Ml\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LZTlExKM7:TR?= MV23NkBp MXXEUXNQ NYXae|JEUUN3ME2xNEDPxE1? NHHzT40zOzh2NECzPC=>
SN12C NGjLS5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlz1NVAh|ryP NXLwOnZ4PzJiaB?= NF[0UHVFVVOR NWq4XIZbUUN3ME2xNEDPxE1? MVGyN|g1PDB|OB?=
SNB-19 M1vPcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rublExKM7:TR?= MkX6O|IhcA>? MnL3SG1UVw>? Mn7kTWM2OD1zMDFOwG0> M4DFPVI{QDR2MEO4
SNU-5 NHTaSnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVi5doFOOTBizszN NGTSdmc4OiCq M1zHNWROW09? NIPUelJKSzVyPUGwJO69VQ>? MVmyN|g1PDB|OB?=
SNU-16 MnXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXwNVAh|ryP MoPmO|IhcA>? M3O4W2ROW09? NXHZPW9zUUN3ME2xNEDPxE1? NInj[lkzOzh2NECzPC=>
SNU-398 NH;leXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\QS4UyOCEQvF2= MkGyO|IhcA>? M4LwRWROW09? MUPJR|UxRTFyIN88US=> NInHe4IzOzh2NECzPC=>
SNU-449 NYHCe21QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEOyUHcyOCEQvF2= M1XXfVczKGh? MoHxSG1UVw>? NFnwOFlKSzVyPUGwJO69VQ>? M1qyUlI{QDR2MEO4
SR Mmi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nFflExKM7:TR?= NWjxemtuPzJiaB?= MXvEUXNQ M4X3U2lEPTB;MUCg{txO MWWyN|g1PDB|OB?=
ST486 M4PKZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3UNVAh|ryP MkHSO|IhcA>? NHT1TYpFVVOR MVzJR|UxRTFyIN88US=> Mlz3NlM5PDRyM{i=
SW579 M1[4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnyelExOTBizszN MXu3NkBp MVnEUXNQ MXvJR|UxRTFyIN88US=> NHvEe4ozOzh2NECzPC=>
SW684 M4HoRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnS3NVAh|ryP NGrHZlc4OiCq MX;EUXNQ NHe5SotKSzVyPUGwJO69VQ>? MVmyN|g1PDB|OB?=
SW-780 NFrM[m1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHpdJUyOCEQvF2= NW[5SpR[PzJiaB?= NXPhO2tkTE2VTx?= NXvYWJZnUUN3ME2xNEDPxE1? MljGNlM5PDRyM{i=
SW900 NYPZdYQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDRSpNGOTBizszN NGjIU3o4OiCq M1vJ[WROW09? MoC3TWM2OD1zMDFOwG0> NF;MdW4zOzh2NECzPC=>
SW1088 M{TReGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXGxNEDPxE1? MX:3NkBp MUDEUXNQ NUnnVJpkUUN3ME2xNEDPxE1? MYmyN|g1PDB|OB?=
SW1463 NIL0XGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7UXFcyOCEQvF2= NHrHNJE4OiCq NUnvOpdRTE2VTx?= NUS2W3piUUN3ME2xNEDPxE1? MYCyN|g1PDB|OB?=
SW1990 NIHvNIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfDeo04OTBizszN MkLqO|IhcA>? M37MZmROW09? Mmq2TWM2OD1zMDFOwG0> NITucnUzOzh2NECzPC=>
T47D M2HsT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HyNlExKM7:TR?= M2Pz[|czKGh? M3jpfmROW09? MnKyTWM2OD1zMDFOwG0> NF[xVXAzOzh2NECzPC=>
TE381.T M1\nXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\HSlExKM7:TR?= NGLHdmU4OiCq NVLUdlFvTE2VTx?= NGfvPHRKSzVyPUGwJO69VQ>? MmDNNlM5PDRyM{i=
TK-10 M3:wd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zWUlExKM7:TR?= MlPxO|IhcA>? M1;6NGROW09? MmTITWM2OD1zMDFOwG0> MWqyN|g1PDB|OB?=
U2OS M3PWdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGiyXVkyOCEQvF2= MnPmO|IhcA>? NEXqSG5FVVOR NYHNNGhmUUN3ME2xNEDPxE1? MlPiNlM5PDRyM{i=
U251 NGHmZo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV[xNEDPxE1? NYDxZopvPzJiaB?= NFTZUlJFVVOR NIS3N|dKSzVyPUGwJO69VQ>? MmXtNlM5PDRyM{i=
UACC-812 NF3uV3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPMNVAh|ryP NY\yN5liPzJiaB?= M37wc2ROW09? NGPEe|VKSzVyPUGwJO69VQ>? Mly0NlM5PDRyM{i=
YAPC M1jlT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGO3bW0yOCEQvF2= NXrKb5FiPzJiaB?= MUTEUXNQ MkDBTWM2OD1zMDFOwG0> M{L5TlI{QDR2MEO4
ZR-75-1 M1Pxe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLFNVAh|ryP M4GyclczKGh? NYSycGpYTE2VTx?= NFfpRW1KSzVyPUGwJO69VQ>? MUGyN|g1PDB|OB?=
A375 MUPGeY5kfGmxbjDhd5NigQ>? MYmxMlIh|ryP NFrXenE1KGh? NIPFZYVFVVOR NFTVWIRKdmirYnn0bY9vKG:oIIDoc5NxcG:{eXzheIlwdiCxZjDNSWstKEWUSzygZY5lKFN4UB?= M4S3N|IzOzh7NEex
YUSIT1 NIrrNW1HfW6ldHnvckBie3OjeR?= NFfPTJFFVVOR M{\pTpJm\HWlZXSgd4Vve2m2aY\peJkhf2m2aDDJR|UxKD5iMD61JO69VQ>? MW[yNlM5QTR5MR?=
MeWo M{OwOGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MV3EUXNQ NVPKRZQzUUN3MDC9JFk5PyCwTR?= NVHScXZPOjZyMUi1NlQ>
WiDr NEjoU49Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYTPPXVbTE2VTx?= NGe0XYZKSzVyIE2gO|Yhdk1? M4\RVVI3ODF6NUK0
Colo-205 NH7neJVHfW6ldHnvckBie3OjeR?= NF3ofIcyKM7:TR?= M1\hWlQh\A>? Mlj2SG1UVw>? MoftTY5lfWOnZDDhJIhq\2iueTDjc41x[XKjYnzlJINwdXCjY4Tpc44heGinbn;0fZBm MojpNlU{QDFzNUK=
RBW-1 NUfVWnNiTnWwY4Tpc44h[XO|YYm= NHrzbnUyKM7:TR?= NWS1PWdWTE2VTx?= NHHzSnpPdyC{ZXT1Z5Rqd25ib3[gUYVsKDFxMjDwbI9{eGixconsZZRqd25? NInkS|kzPDh6NU[5NC=>
RBO-1 MXvGeY5kfGmxbjDhd5NigQ>? MX:xJO69VQ>? Mo\SSG1UVw>? MlHHTY5pcWKrdHnvckBw\iCPZXugNU8zKHCqb4PwbI9zgWyjdHnvci=> NIXHS|MzPDh6NU[5NC=>
RBO-2 M1TtfWZ2dmO2aX;uJIF{e2G7 NWXWcGliOSEQvF2= Mn3lSG1UVw>? M3;oeGlvcGmkaYTpc44hd2ZiIF3lb{AyNzJicHjvd5Bpd3K7bHH0bY9v NWfadoJCOjR6OEW2PVA>
RBOW MmO0SpVv[3Srb36gZZN{[Xl? M2S2UFEh|ryP MXHEUXNQ M4e2NmlvcGmkaYTpc44hd2ZiIF3lb{AyNzJicHjvd5Bpd3K7bHH0bY9v NXfFWVFyOjR6OEW2PVA>
M257 NET0XndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnrWHBYOTByIH7N M3Lud|czKGh? NGLV[WNFd2W|IH7veEBqdmirYnn0JJBzd2yrZnXyZZRqd25ib3[gUVI2PyClZXzsJIhiemKxdYLpcochf2muZDD0fZBmKEKUQV[= M1nkdFI{OzF5NES2
LCP NGLFSYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDacHE1OTByIH7N NYfJNYh7PzJiaB?= M4rHbGlvcGmkaYTpc44hd2ZicILvcIln\XKjdHnvckBw\iCOQ2CgZ4VtdCCqYYLic5VzcW6pIFLSRWYhXjZyMGKgcZV1[W62YYTpc44> NWH4boVPOjN|MUe0OFY>
WM266 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYqxNFAhdk1? MYW3NkBp M3HMVmlvcGmkaYTpc44hd2ZicILvcIln\XKjdHnvckBw\iCZTUK2OkBk\WyuIHjhdoJwfXKrbnegRnJCTiCYNkCxSEBufXSjboTheIlwdg>? NIr5TXEzOzNzN{S0Oi=>
M257 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUKxNFAhdk1? M3LKR|czKGh? M1HZWWRw\XNibn;0JIlvcGmkaYSgSXJMOS1{IIDoc5NxcG:{eXzheIlwdiCrbjDNNlU4KGOnbHygbIFz[m:3cnnu[{B4cWymIIT5dIUhSlKDRh?= MkW1NlM{OTd2NE[=
LCP MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XnSFExOCCwTR?= NETt[lM4OiCq MWPJcohq[mm2IFXST|EuOiCyaH;zdIhwenmuYYTpc44hcW5iTFPQJINmdGxiaHHyZo92emmwZzDCVmFHKFZ4MEDSJI12fGGwdHH0bY9v M1q0OFI{OzF5NES2
WM266 MnX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYexNFAhdk1? M1nmTlczKGh? MV\Jcohq[mm2IFXST|EuOiCyaH;zdIhwenmuYYTpc44hcW5iV12yOlYh[2WubDDoZZJjd3W{aX7nJGJTSUZiVk[wNGQhdXW2YX70ZZRqd25? NXrVTXlKOjN|MUe0OFY>

... Click to View More Cell Line Experimental Data
体内研究 Dabrafenib（口服）抑制B-RafV600E突变的黑色素瘤（A375P）的生长，在免疫受损小鼠中皮下注射结肠癌（Colo205），Dabrafenib（口服）同样能抑制肿瘤生长。 [1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度 (25°C)

体外 DMSO 30 mg/mL (57.74 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)：
30% PEG400+0.5% Tween80+5% propylene glycol 		8 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 519.56
化学式

C23H20F3N5O2S2
CAS号 1195765-45-7
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量：

总分子量：g/mol

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03272464 Recruiting Melanoma Massachusetts General Hospital|Incyte Corporation November 30 2018 Phase 1
NCT03668431 Recruiting Metastatic Colorectal Cancer Massachusetts General Hospital|Novartis|Stand Up To Cancer October 15 2018 Phase 2
NCT02672358 Withdrawn Non-Small-Cell Lung Cancer Novartis Pharmaceuticals|Novartis September 3 2018 Phase 2
NCT03551626 Recruiting Malignant Melanoma Novartis Pharmaceuticals|Novartis August 29 2018 Phase 3
NCT03455764 Recruiting Melanoma Dana-Farber Cancer Institute|Novartis June 22 2018 Phase 1|Phase 2
NCT03553329 Completed Unresecable Stage IIIc or IV Melanoma Poitiers University Hospital June 2 2018 --

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

  • * 必填项
Selleck产品目录册

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

  • 泛Raf抑制剂

    AZ 628 : Pan-Raf inhibitor, BRAF, IC50=105 nM; BRAFV600E, IC50=34 nM; c-Raf-1, IC50=29 nM.

  • FDA批准的Raf抑制剂

    Sorafenib Tosylate : Approved by FDA for advanced renal cancer。

  • 最新的Raf抑制剂

    TAK-632 New : Potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf, respectively, showing less or no inhibition against other tested kinases.

相关Raf产品

  • LY3009120 New

    LY03009120是一种有效的泛Raf抑制剂，在A375细胞中对A-raf，B-Raf，和 C-Raf的IC50分别为44 nM，31-47 nM，和 42 nM。Phase 1。

  • Ravoxertinib (GDC-0994) New

    GDC-0994 是一种有效的，可口服的， 具有选择性的 ERK1/2 抑制剂, 其IC50分别为1.1 nM和0.3 nM。 Phase 1。

  • Ulixertinib (BVD-523, VRT752271) New

    Ulixertinib (BVD-523, VRT752271)是有效的可逆ERK1/ERK2抑制剂，其抑制ERK2的IC50<0.3 nM 。Phase 1。

  • Vemurafenib (PLX4032, RG7204)

    Vemurafenib (PLX4032, RG7204)是一种新型有效的B-RafV600E抑制剂，IC50为31 nM。Vemurafenib对B-RafV600E的选择性比对野生型B-Raf的选择性高10倍，在细胞实验中，选择性可高100倍以上。

    Features:PLX4032是新型有效的B-RAFV600E 肿瘤蛋白抑制剂。

  • Sorafenib

    Sorafenib是Raf-1, B-Raf和VEGFR-2的多重激酶抑制剂，无细胞试验中IC50分别为6 nM, 22 nM和90 nM。

  • Sorafenib Tosylate

    Sorafenib Tosylate是一种酪氨酸激酶(VEGFR和PDGFR)和RAF/MEK/ERK级联抑制剂，同时作用于Raf-1，wtBRAF和V599EBRAF，IC50分别为6 nM， 22 nM和38 nM。

  • PLX-4720

    PLX-4720是一种有效的，选择性的B-RafV600E抑制剂，无细胞试验中IC50为13 nM，同样有效地作用于c-Raf-1(Y340D和Y341D突变型)，作用于B-RafV600E比作用于野生型B-Raf选择性高10倍。

  • TAK-632

    TAK-632是强效的泛Raf抑制剂，无细胞试验中对B-Raf(wt)和C-Raf的IC50分别为8.3 nM and 1.4 nM， 对其他被测试的酶抑制效果较差或者没有效果。

  • GDC-0879

    GDC-0879是一种新型有效的，选择性B-Raf抑制剂，在A375和Colo205细胞中IC50为0.13 nM，对c-Raf也有抑制作用；对其他蛋白激酶没有抑制作用。

  • GW5074

    GW5074是一种有效的，选择性的c-Raf抑制剂，IC50为9 nM，对JNK1/2/3， MEK1， MKK6/7， CDK1/2， c-Src， p38 MAP， VEGFR2和c-Fms没有抑制活性。

Tags: 购买Dabrafenib (GSK2118436) | Dabrafenib (GSK2118436)供应商 | 采购Dabrafenib (GSK2118436) | Dabrafenib (GSK2118436)价格 | Dabrafenib (GSK2118436)生产 | 订购Dabrafenib (GSK2118436) | Dabrafenib (GSK2118436)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID